Is Australian Pharmaceutical Industries Ltd a buy at this share price?

Australian Pharmaceutical Industries Ltd (ASX:API) held its AGM on Wednesday and provided half-year guidance. Are its shares a buy?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On Wednesday afternoon it was the turn of Australian Pharmaceutical Industries Ltd (ASX: API) shareholders to gather for their annual general meeting.

Of the many things discussed by CEO-elect Richard Vincent, chief among them was news about how the business was tracking so far in FY 2017.

He revealed that the company behind the Priceline, Soul Pattinson, and Pharmacy Advice brands expects to report a half-year profit of $29 million, up 14.6% on the prior corresponding period.

Whilst this is a solid result, it is a touch slower than last year's profit growth of 18.1%. This may explain why its shares sank slightly after the news was revealed.

Total sales growth in the Priceline network year to date is 3.6%, with like-for-like sales increasing 1.4% up to the Christmas period.

Since then however like-for-like sales growth has been slower than normal, coming in at just 0.6% for the week ending January 14.

After years of meteoric growth, I can't say I'm too surprised to see Priceline's like-for-like growth slowing a touch. But this level of growth is quite a concern.

When judging retail shares the key metric I look for is like-for-like sales growth. At the current level I wouldn't be in a rush to invest in its shares.

Right now I would class Australian Pharmaceutical Industries as a hold. I would suggest investors wait until there is a marked improvement in its like-for-like sales growth before making an investment.

Its rival Sigma Pharmaceutical Limited (ASX: SIP), which operates the Amcal and Chemist King brands, last reported like-for-like sales growth of 7.2%.

With both shares trading on similar earnings multiples, Sigma is starting to look like the more attractive option in my opinion.

All being well Australian Pharmaceutical Industries' new CEO will be able to reignite the Priceline brand. But until then I'm going to sit this one out.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »